LatestFDA Expert Committee Reviews Capricor Therapeutics' Duchenne Muscular Dystrophy Treatment
Cannabis

Federal Survey Shows Decline in Adolescent Cannabis Use in 2025

Raúl del Pino
Summary

The 2025 National Survey on Drug Use and Health (NSDUH) reports a significant decline in annual adolescent cannabis consumption to 8.7%, marking an important shift in youth substance use patterns. This decrease contrasts with evolving consumption trends among adults, suggesting differentiated public health trajectories between age groups. The data provides critical insights for healthcare providers and policymakers developing prevention and intervention strategies. For Puerto Rico's health systems, these findings underscore the importance of evidence-based approaches to adolescent substance use prevention and monitoring. Understanding these epidemiological trends helps inform clinical practices and resource allocation for youth mental health and substance use treatment services.

Originally published on

Cannabis Magazine

By Raúl del Pino

Read full article(opens in new tab)

Fetched: July 29, 2026 at 10:02 AM

Related News

More news you might be interested in

View all
THC and CBD Reduce Agitation in Advanced Dementia, Study Shows
Cannabis
Alzheimer's Disease

THC and CBD Reduce Agitation in Advanced Dementia, Study Shows

A new clinical trial presented at the Alzheimer's Association International Conference demonstrates that an oral formulation combining THC and CBD significantly reduced agitation in patients with advanced dementia receiving hospice care. The study, while not yet peer-reviewed, offers promising evidence that cannabinoid therapy may help manage behavioral symptoms in end-stage dementia patients who often have limited treatment options. Agitation in advanced dementia is a challenging symptom that frequently requires sedative medications with significant side effects. These findings suggest cannabinoid-based treatments could provide a potentially safer alternative for improving quality of life in vulnerable populations. Further peer-reviewed publication and larger-scale studies are needed to establish optimal dosing and long-term safety profiles.

1 hour ago
Revista Cáñamo
India Leaves Public Cannabis Law Review Without Response as Court Deadline Passes
Cannabis

India Leaves Public Cannabis Law Review Without Response as Court Deadline Passes

India's Delhi High Court deadline of July 23rd for the government to review cannabis restrictions has passed without public resolution. The legal silence exposes significant contradictions in India's cannabis regulations, which inconsistently distinguish between plant parts, authorized medical uses, and criminal penalties. This regulatory ambiguity affects patients seeking access to cannabis-based treatments for various medical conditions. The unresolved review highlights the urgent need for regulatory clarity to align Indian law with emerging medical evidence supporting therapeutic cannabis applications. The delayed response may impact future medical cannabis access and research opportunities in the region.

2 hours ago
Revista Cáñamo
Cannabis Species: Understanding Ruderalis and Hybrid Strains
Cannabis

Cannabis Species: Understanding Ruderalis and Hybrid Strains

Cannabis is typically classified into three main species: sativa, indica, and ruderalis, each with distinct characteristics and therapeutic properties. While federal illegality has limited comprehensive botanical research, cultivators frequently crossbreed top strains from different species to create hybrid varieties with combined effects. These hybrids allow patients and consumers to access customized cannabinoid profiles tailored to specific therapeutic needs. Understanding the differences between pure species and hybrids is essential for informed selection of medical cannabis products in regulated markets like Puerto Rico's medical marijuana program.

6 hours ago
Cannabis Now
Cannabis
DepressionMajor Depressive Disorder

Study Links Psychedelics and Ketamine to Common Neuroimmune Signals

Groundbreaking research combines patient-derived cells, proteomics, and clinical ketamine data to identify shared neuroimmune biomarkers underlying rapid antidepressant responses. The study reveals that both psychedelic compounds and ketamine activate similar immune signaling pathways in the brain, offering crucial insights into how these treatments produce fast-acting antidepressant effects. These findings could enable identification of biomarkers to predict patient response and develop more effective rapid-acting treatments for major depressive disorder. The research bridges the gap between traditional pharmacology and emerging psychedelic therapeutics, advancing precision medicine approaches for treatment-resistant depression.

7 hours ago
Cannabis Magazine